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social, economic, and organizational issues that need to be addressed 
as the field of personalized medicine grows. As a result, improve 
patient care in the future.
Conclusion: Personalized medicine has the potential to revolu-
tionize care. However, current challenges and concerns need to be 
addressed to enhance uptake and funding to benefit patients in the 
future. Clinical pharmacologists can play critical role with advising 
authorities on the potential value of new diagnostic and prognostic 
tests as well as new targeted therapies.
Funding Sources: This work was in part supported by grants from 
the Karolinska Institutet, Sweden, as well as grants from the Swedish 
Research Council (VR 2011-3440 and VR 2011-7381). The authors 
have no other conflicts of interest.
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Introduction: The statin lipid-lowering efficacy and safety varies 
widely among patients. This is mainly interpersonal differences can 
be explained by genetic factors. The purpose of this study was to 
investigate the prevalence of allelic variants (polymorphism) of the 
gene SLCO1B1 * 5 (c.521T> C, rs4149056), which encodes a poly-
peptide involved in the removal of statins by the liver into the bile, 
as well as prediction of myopathy in patients who are to the use of 
statins. The frequency of genotypes in SLCO1B1 in the Russian popu-
lation is not known in other European ethnic groups is 8% to 20%.
Patients (or Materials) and Methods: The study is based AGL 
Hospital Road station Yaroslavl OJSC “Russian Railways” GBOU 
VPO Yaroslavl State Medical Academy, Russian Ministry of Health 
in 2012–2013. The study included 377 patients with dyslipidemia 
and systemic atherosclerosis. Of these, 226 men (59.95%) and 151 
women (40.05%); the mean age was 52.58 12.21. All patients under-
went determination of single nucleotide polymorphisms SLCO1B1 * 
5 using reagent “SNP-Express” by real-time PCR thermocycler with 
IQ 5 (firm Bio-Rad).
Results: Identified gene polymorphisms SLCO1B1 * 5: heterozygous 
genotype s.521 vehicle in 106 patients (28.12%) and homozygous 
genotype CC s.521 - in 14 patients (3.71%), which is associated with 
an increased risk of myopathy with statins and the need for correction 
of the maximum dose to be lower compared with the TT genotype 
s.521 (“wild” type.)
Conclusion: The frequency of the heterozygous genotype (s.521TS) 
is 28%, and homozygous genotype (s.521SS) - 4% of patients with 
dyslipidemia and systemic atherosclerosis, which requires a reduc-
tion of the therapeutic dose of statins to one half and one quarter, 
respectively. Thus, the holding of pharmacogenetic testing can be 
useful for your personal selection of the dose of statin to maximize 
the effectiveness and safety of treatment.
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Introduction: CYP2D6 codes for a protein that is vastly involved 
in metabolism of various substances. Different metabolic profiles 
determine the processing of xenobiotics and endobiotics, thereby 
influencing disease risk, therapeutic efficacy and side effects, or toxic-
ity of xenobiotics. The aim of this work was to characterize CYP2D6 
polymorphisms and predict metabolic profiles in the Portuguese 
population.
Patients (or Materials) and Methods: A total of 300 Portuguese 
unrelated adult healthy volunteers were studied. Genetic analysis 
included allelic discrimination and copy number determination 
with TaqMan® probes by real-time PCR and allele duplications of 
CYP2D6*1, CYP2D6*2, CYP2D6*4, and CYP2D6*10 were con-
firmed by long PCR and PCR-RFLP.
Results: The percentages of poor and ultrarapid metabolizers found 
in this Portuguese population were 6.3% and 4.7%, respectively. 
Accordingly, is it estimated that, taking into account the number 
of inhabitants estimated by CENSUS 2011 (10,562,178), there are 
~665,417 poor metabolizers (PM) and 496,422 ultrarapid metaboliz-
ers (UM) in Portugal. The frequency of extensive metabolizers (EM) 
and intermediate metabolizers (IM) is in agreement with previous 
studies.
Conclusion: The allelic frequencies were similar to other stud-
ies of European populations, with some exceptions, such as for 
CYP2D6*10, which is higher in Portuguese population and for 
CYP2D6*6 and duplication of *1 and *2, that present lower frequen-
cies in the present study. After this study, we could evaluate the most 
important CYP2D6 variants in the Portuguese population and pre-
dict metabolic profiles. The data presented here are noteworthy for 
determination of the genetic variability influencing CYP2D6 activity, 
to improve the effectiveness and safety in the xenobiotics exposure, 
working also as a strong tool for clinical practice and development 
of individualized pharmacotherapy.
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Introduction: CYP2C9 is involved in the metabolism of drugs 
such as warfarin, losartan, fluoxetine, and NSAIDs. The frequency 
of CYP2C9*2, allele causing decreased enzyme activity, has been 
reported to be lower in Amerindian and Admixed populations (from 
Cuba, Nicaragua, Ecuador, and Mexico), than in Spanish-Caucasian 
populations.1,2 The aim of this study was to determine CYP2C9 
allele frequencies in 3 Costa Rican ethnic groups and to compare 
the results with frequencies previously reported for Hispanic popu-
lations.
Patients (or Materials) and Methods: The CYP2C9 alleles (*2, *3 and 
*6) were analyzed by real-time-PCR among 375 healthy individuals 
belonging to 3 ethnic groups living in Costa Rica: Amerindians (AM; 
n = 193), Afro-Caribbeans (AC; n = 45) and Costa Rican Mestizo 
population (CRM; n = 137). These frequencies were compared with 
a population of Spaniards (SP n = 327) 2 previously published.
Results: The frequency of CYP2C9*2 was significantly lower in the 
AM (2.8%) and CRM (7.7%) than in the SP group (16%; P < 0.05). 
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Among Costa Ricans, CYP2C9*2 was also lower in the AM than 
in the CRM population (P < 0.05). Moreover, the frequency of 
CYP2C9*3 in the CRM, AM and AC groups was 3.6%, 2.1% and 
3.3%, respectively. CYP2C9*6 was not detected.
Conclusion: Present data support that the CYP2C9*2 frequency is 
lower in Amerindian populations than Caucasians, suggesting the 
importance of pharmacogenetic studies for optimizing drug dosages 
in different populations according to their ancestry.
Funding Sources: This study was supported by the University of 
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of Junta de Extremadura (11A002), Consejería de Empleo, Empresa 
e Innovación and Fondo Social Europeo (FSE) Grant PD10199 
(MEGN) and the Network Red Iberoamericana de Farmacogenética 
y Farmacogenómica. PI10/02758.
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Introduction: The aim of this research was to study the preva-
lence of methylenetetrahydrofolate reductase (MTHFR) C677T 
gene polymorphismsand homocysteine concentration in male 
patients, European race, with mild to moderate essential hyper-
tension.
Patients (or Materials) and Methods: The investigations were per-
formed in 35 patients (mean age, 50.0 [5.9] years). All the patients 
had family history of essential hypertension. The higher prevalence 
of risk factors was revealed: smoking – 62.8% patients, overweight – 
71.4%, dyslipidemia – 48.6%. The following defeats of targets were 
diagnosed: left ventricular hypertrophy – 40% patients, ultrasonic 
signs of carotids atherosclerosis – 82.8% patients. To identify muta-
tions С677Т of a gene MTHFR polymerase chain reaction with the 
subsequent restriction amplifications was used.
Results: Genotypes by MTHFR were distributed as follows: homozy-
gotes C allele (СС genotype) was defined in 19 patients (55.9%); 
heterozygotes (СТ genotype) in 11 patients (32.3 %); homozygotes 
Т allele ( TT genotype) in 4 patients (11.8%). Homocysteine concen-
tration in patients with СС genotype was authentically lower than 
in patients with СT and TT genotype (11.34 [0.64] vs 15.33 [0.57] 
mkmol/L; P < 0.001).
Conclusion: Thus, in male patients, European race, with mild to 
moderate essential hypertension the prevalence of mutant allele T, 
determining the reduction of enzyme activity MTHFR, was 44.1%. 
The presence of mutant allele T was associated with a higher level of 
homocysteine concentration.
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Introduction: Raloxifene is a selective oestrogen receptor modulator 
commonly used for the treatment of postmenopausal osteoporosis. 
The drug is significantly associated with an increased risk of deep 
venous thrombosis and pulmonary embolism, probably because of 
its estrogenic effects on the coagulation and fibrinolytic systems. It is 
known that many drugs vary in potency and/or toxicity according to 
a dosing time. Because both the coagulation and fibrinolytic systems 
exhibit circadian rhythms, such adverse effects of raloxifene could be 
diminished by optimizing a dosing time. The aim of the present study 
was to investigate the effects of dosing time of raloxifene on markers 
of coagulation and fibrinolysis, as well as of bone metabolism.
Patients (or Materials) and Methods: Postmenopausal patients with 
osteoporosis were randomly allocated to 2 groups: 1 received 60-mg 
raloxifene once daily in the morning, whereas the other received 
60-mg raloxifene in the evening, for 12 months.
Results: In both groups, the activity of coagulation Factors IX and 
XII significantly increased after 12 months treatment compared with 
baseline. The activity of coagulation Factors II and V, and levels 
of markers of bone metabolism (ie, bone alkaline phosphatase and 
tartrate-resistant acid phosphatase 5b) decreased in both groups. 
The changes in these markers did not differ between the 2 groups. In 
contrast, the plasma concentration of plasminogen activator inhibi-
tor-1 increased in the patients with the morning dose but not in the 
patients with the evening dose.
Conclusion: Because the elevated concentration of plasminogen acti-
vator inhibitor-1 is shown to be associated with the risk of venous 
thromboembolism, these data suggest that the evening dose of ralox-
ifene is relatively safe dosage regimen.
Disclosure of Interest: None declared.
PP162—thorouGh qt stuDy with 
PonesimoD, a selective s1P1 recePtor 
moDulator
M. Hoch1*; A. Vaclavkova2; R. Stoltz3; P. Brossard1; and  
J. Dingemanse1
1Clinical Pharmacology; 2Drug Safety, Actelion Pharmaceuticals 
Ltd, Allschwil, Switzerland; and 3Covance Clinical Research Unit, 
Evansville, United States
Introduction: Ponesimod is a selective sphingosine-1 phosphate 
(S1P1) receptor modulator currently in clinical development for 
multiple sclerosis and plaque psoriasis. Drug-induced prolongation 
of the QT interval can lead to torsades de pointes and sudden cardiac 
death. The aim of this study was to assess whether ponesimod has 
a negative QT/QTc effect as per ICH E14 guidance in a thorough 
QT/QTc study.
Patients (or Materials) and Methods: This was a single-center, dou-
ble-blind, placebo- and positive-controlled (400-mg moxifloxacin), 
parallel group with nested crossover, up-titration study in 116 healthy 
male and female subjects (58 subjects on ponesimod and 58 subjects 
on moxifloxacin/placebo). All subjects received placebo for ponesi-
mod on day –1. In treatment group A, ponesimod was administered 
orally once daily for 22 days (10 mg on days 2–4, 20 mg on days 5–7, 
40 mg on days 8–12, 60 mg on days 13–15, 80 mg on days 16–18, 
and 100 mg on days 19–23). In addition, subjects received placebo 
